Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study
| Autor: | Eric D. Peselow, Steven Clevenger, Waguih William IsHak |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder Lithium (medication) Pharmacology Lithium Relapse prevention 03 medical and health sciences 0302 clinical medicine Antimanic Agents Internal medicine medicine Secondary Prevention Humans Pharmacology (medical) Bipolar disorder Valproic Acid business.industry Proportional hazards model Carbamazepine Middle Aged medicine.disease Confidence interval 030227 psychiatry Psychiatry and Mental health Mood Treatment Outcome Female business Post-Exposure Prophylaxis 030217 neurology & neurosurgery medicine.drug Follow-Up Studies |
| Zdroj: | International clinical psychopharmacology. 31(4) |
| ISSN: | 1473-5857 |
| Popis: | Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mood-stabilizing agents: lithium (Li), valproic acid (VPA), and carbamazepine (CBZ), in preventing relapse episodes. A total of 225 patients with bipolar disorder were included in the present analysis. Patients taking Li, VPA, or CBZ were followed up for up to 124 months, until suffering a manic, mixed, or depressive episode (relapse), or until the end of the study/study termination (no relapse), whichever came first. The median unadjusted survival time was 36 months for patients taking VPA, 42 months for patients taking CBZ, and 81 months for patients taking Li. These results indicate that patients stayed longer on Li, suggesting that it might have been better tolerated than either CBZ or VPA. χ-Analysis showed that patients taking Li were significantly less likely to experience relapse during the observational period than patients taking either VPA or CBZ (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|